Ophthalmic gel composition

A technology of ophthalmic gel and composition, which is applied in the field of ophthalmic gel composition and its preparation, and can solve problems such as difficulty in absorption, loss, foreign body sensation in the eyes, etc.

Active Publication Date: 2011-09-21
SHANGHAI HAOHAI BIOLOGICAL TECH
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The common epidermal growth factor eye drops currently used clinically are easily lost from the eye wound during use, and it is difficult to achieve the desi

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ophthalmic gel composition
  • Ophthalmic gel composition
  • Ophthalmic gel composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Preparation of Ophthalmic Gel Composition I

[0055] The components in the prescription are shown in the table below

[0056] component name

dose

% of total

role in prescription

recombinant human epidermal growth factor

(active protein)

1×10 7 IU

0.002％

Main drug

sodium hyaluronate

1.5g

0.15％

Main drug

bovine serum albumin

1.0g

0.1％

stabilizer

Alanine

3.0g

0.3％

Nutrients

[0057] Glycine

3.0g

0.3％

Nutrients

arginine

3.0g

0.3％

Nutrients

Sodium chloride

8.5g

0.85％

isotonicity regulator

Sodium dihydrogen phosphate monohydrate

1.7g

0.17％

pH regulator

Water for Injection

978.28g

97.828％

solvent

[0058] Preparation:

[0059] 1. In a 100-grade purification environment, weigh 1.5g of sodium hyaluronate and 1.0g of bovine seru...

Embodiment 2

[0064] Preparation of Ophthalmic Gel Composition II

[0065] The components in the prescription are shown in the table below

[0066] component name

dose

% of total

role in prescription

recombinant human epidermal growth factor

(active protein)

5×10 6 IU

0.001％

Main drug

sodium hyaluronate

1.0g

0.1％

Main drug

bovine serum albumin

1.0g

0.1％

stabilizer

Alanine

3.0g

0.3％

Nutrients

Glycine

3.0g

0.3％

Nutrients

Sodium chloride

8.5g

0.85％

isotonicity regulator

Disodium phosphate

2.2g

0.22％

pH regulator

Sodium dihydrogen phosphate

0.2g

0.02％

pH regulator

Water for Injection

981.09g

98.109％

solvent

[0067] Preparation:

[0068] 1. In a 100-grade purification environment, weigh 1.0g of sodium hyaluronate and 1.0g of bovine serum albumin in a 10...

Embodiment 3

[0073] Preparation of Ophthalmic Gel Composition III

[0074] The components in the prescription are shown in the table below

[0075] component name

dose

% of total

role in prescription

recombinant human epidermal growth factor

(active protein)

1×10 6 IU

0.0002％

Main drug

sodium hyaluronate

0.5g

0.05％

Main drug

bovine serum albumin

1.0g

0.1％

stabilizer

Disodium phosphate

2.2

0.22％

pH regulator

Sodium dihydrogen phosphate

0.2g

0.02％

pH regulator

Sodium chloride

8.5g

0.85％

isotonicity regulator

Water for Injection

987.58g

98.758％

solvent

[0076] Preparation:

[0077] 1. In a class 100 purification environment, weigh 0.5g of sodium hyaluronate and 1.0g of bovine serum albumin into a 1000ml volumetric flask according to the prescription, add about 300ml of water for injection an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an ophthalmic gel composition. Each gram of the composition comprises necessary components of: 1000 to 100000 IU (international unit) of epidermal growth factors (EGF), 0.5 to 3.5 mg of hyaluronate sodium, and rest components of pharmaceutical acceptable carriers. The invention also discloses a preparation method and a purpose of the composition.

Description

technical field [0001] The invention relates to the field of ophthalmology, in particular to an ophthalmic gel composition and its preparation method and application. Background technique [0002] Corneal epithelial disease is one of the most common corneal diseases in ophthalmology clinics. The etiology includes mechanical injury (epithelial abrasion, calculus, corneal contact lens), drug toxicity, nerve paralysis or exposure keratitis, and others (including ultraviolet rays, cosmetics, vitamin A deficiency, diabetes, etc.). In recent years, corneal epithelial diseases have become more and more serious due to various reasons such as the increase of wearers of contact lenses, the popularization of computers, the widespread use of domestic anti-fatigue eye drops (which contain preservatives), and the long-term abuse of antibiotic eye drops. increase. The human cornea is located at the front of the eyeball, directly in contact with the outside world, and has many chances of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/18A61K9/00A61P27/02A61K31/728
Inventor 任彩霞侯永泰陈亚玲吴剑英魏欣
Owner SHANGHAI HAOHAI BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap